INTRODUCTION
============

Idiopathic inflammatory myopathies encompass a heterogeneous group of systemic autoimmune diseases, including polymyositis (PM), which is characterized by symmetrical proximal and progressive muscle weakness of the limbs and dermatomyositis (DM), which, in addition to muscle involvement, includes skin abnormalities, such as heliotrope and Gottron\'s papules ([@b1-cln_68p621],[@b2-cln_68p621]).

Viral infections, such as herpes zoster (HZ), have been increasingly reported in individuals with systemic autoimmune diseases. Among patients with systemic lupus erythematosus, for instance, there is an HZ prevalence of 4.5% ([@b3-cln_68p621]) and an incidence of 6.4--58.7 events/1,000 patient-years ([@b3-cln_68p621],[@b4-cln_68p621]). Corticosteroids ([@b3-cln_68p621]) and immunosuppressive agents ([@b4-cln_68p621]--[@b6-cln_68p621]), disease activity ([@b5-cln_68p621]--[@b8-cln_68p621]) and the presence of anti-Sm autoantibodies ([@b8-cln_68p621]) number among the possible risk factors for HZ in this population. The incidence of HZ in rheumatoid arthritis is 9.96 cases/1,000 patient-years ([@b9-cln_68p621]), and the risk factors in this cohort include older age (\>45 years old), the presence of cancer, chronic lung disease, corticosteroid usage ([@b10-cln_68p621]), exposure to immunosuppressive ([@b10-cln_68p621]) and immunobiological therapies ([@b11-cln_68p621]) and immune system dysregulation ([@b12-cln_68p621]).

Through a few epidemiological studies, HZ in DM/PM has been investigated within the context of other opportunist infections or by examining a few myositis cases with HZ ([@b13-cln_68p621]--[@b15-cln_68p621]). Thus, Fardet et al. ([@b13-cln_68p621]) analyzed the incidence, risk factors, and severity of HZ in 121 patients with DM. However, these authors evaluated HZ and herpes simplex in DM patients with and without malignancy. Marie et al. ([@b14-cln_68p621]) assessed several opportunistic and severe infections in 279 patients with DM/PM for a period of 13 years, but they found only three cases of HZ. Nagaoka et al. ([@b15-cln_68p621]) analyzed the incidence of HZ in 22 patients with DM/PM over a period of 10 years. Five patients had histories of this viral infection, which predominantly occurred in the remission stage of the disease, showing no relationship with drug therapies.

Due to the dearth of publications on the topic, the aim of this study was to analyze the prevalence, risk factors and outcomes of HZ in our cohort of DM/PM patients.

MATERIALS AND METHODS
=====================

### Study population, clinical assessment and data collection

Between January 1991 and January 2012, 230 consecutive patients with DM or PM and who fulfilled at least four of the five Bohan and Peter ([@b2-cln_68p621]) criteria were followed at a tertiary hospital. Twenty-four subjects (10.4%) in this group had histories of HZ. Of the remaining patients without HZ, a control group of 48 patients (two controls for every HZ patient) was formed and matched by gender, disease type (DM or PM), age at the onset of myositis and disease duration. The study was approved by the local Research Ethics Committee.

Demographics, drug therapy and clinical and laboratory data were retrospectively obtained through a systematic review of all patient medical records. Drug therapy and laboratory data were based on the time of the DM/PM diagnosis and the season in which the HZ event occurred, while the clinical manifestations considered were those presenting during the follow-up of these patients.

Constitutional symptoms, skin changes (e.g., heliotrope, Gottron\'s papules, ulcers, photosensitive, calcinosis, and vasculitis), joint involvement (arthralgia and/or arthritis), and gastrointestinal (dysphagia) and respiratory (dyspnea on moderate exertion) manifestations were analyzed.

Creatine kinase (normal range 24--173 IU/L) and aldolase (1.0--7.5 IU/L) were determined using an automated kinetic assay. Leukocyte count, lactate dehydrogenase, alanine aminotransferase and aspartate aminotransferase were also assessed. The erythrocyte sedimentation rate and C-reactive protein levels were evaluated using the Westergren and nephelometry methods, respectively. Autoantibodies against cellular components were determined with indirect immunofluorescence using Hep-2 cells as the substrate. Autoantibody anti-Jo-1 was determined using the Western blotting method.

All of the patients were first started on corticosteroids (prednisone 1 mg/kg/day, administered orally), which were tapered gradually according to clinical and laboratory stability. In cases of high disease severity (dysphagia with risk of aspiration pneumonia, cutaneous vasculitis, or being refractory to oral corticosteroids), intravenous corticosteroids were administered (methyl prednisolone 1 g/day for three consecutive days). The following drugs were used alone or in combination for corticosteroid sparing: azathioprine (2--3 mg/kg/day), methotrexate (20--25 mg/week), cyclosporine (2--3 mg/kg/day), mycophenolate mofetil (2--3 g/day), leflunomide (20 mg/day), cyclophosphamide (0.5--1.0 g/m^2^ of body surface), intravenous human immunoglobulin (1 g/kg/day for two consecutive days) and chloroquine diphosphate (3--4 mg/kg/day).

Herpes zoster information
-------------------------

HZ infection was clinically defined by the appearance of the typical vesicular eruption distributed in a dermatome. The potential complications of HZ, which were listed on the protocol form, included postherpetic neuralgia (persistence of pain for more than one month after the disappearance of the rash) ([@b16-cln_68p621]) and cutaneous dissemination (vesicular lesions outside the primary and adjacent dermatomes) ([@b17-cln_68p621]). All of the lesions were initially evaluated by rheumatologists and then by dermatologists from our service.

The disease status at the time of the HZ diagnosis was defined as (a) partial clinical response (evidence of disease activity within the last 6 months of disease); (b) complete clinical response (6-month continuous period with no evidence of disease activity while still receiving myositis therapy); and (c) clinical remission (6-month continuous period with no evidence of disease activity and no myositis therapy) ([@b17-cln_68p621]). Disease activity was defined as an increase in muscle enzyme sera levels, with clinical evidence of limb muscle weakness at two consecutive medical evaluations.

Statistical analysis
--------------------

Continuous variables are expressed as the means±standard deviations (SDs), as medians with interquartile ranges (IQRs), or as percentages for categorical variables. Student\'s t-test or the Mann-Whitney U-test for continuous variables was employed to evaluate the differences between the DM/PM groups. The 95% confidence intervals (95% CI) were calculated using binomial distribution. All of the variables that significantly differed statistically in the univariable analysis (comparison between patients with and without HZ episodes or with and without neurological sequelae) were selected for adjustment. The sex- and age-adjusted odds ratios (ORs) and 95% CIs were calculated using an unconditional logistic model, and *p*\<0.05 was considered statistically significant.

RESULTS
=======

Demographic and clinical features of patients with and without herpes zoster
----------------------------------------------------------------------------

Over a 21-year follow-up period, 24 (10.4%) of 230 patients had HZ (19 DM cases and 5 PM cases, 3.8:1), and two-thirds were female. The clinical and demographic features of these patients are shown in [Table 1](#t1-cln_68p621){ref-type="table"}. In general, these characteristics were comparable between the groups with and without HZ, except for a higher prevalence of DM in the group with HZ compared to the patients without HZ (*p* = 0.046).

The mean age of the patients with HZ was 44.6±16.8 years (range 21 to 84 years). Demographic and clinical variables of the 24 patients in the HZ group were compared with those of the 48 randomly selected and matched patients without HZ, as shown in [Table 2](#t2-cln_68p621){ref-type="table"}. No differences were detected between the two groups regarding the cumulative clinical manifestations ([Table 2](#t2-cln_68p621){ref-type="table"}). Furthermore, the two groups were comparable in terms of current disease status, laboratory parameters (initial and current) and autoantibodies ([Table 3](#t3-cln_68p621){ref-type="table"}).

All of the HZ patients initially received intravenous acyclovir (30 mg/kg/day).

There was no difference between DM/PM with and without HZ with regard to glucocorticoid therapy (current use, medium dose and cumulative dose over the two previous months). Similarly, immunosuppressive therapy use was similar in both groups ([Table 4](#t4-cln_68p621){ref-type="table"}). However, the patients using chloroquine diphosphate had a 5.98-fold (95% CI, 1.66--22.26) greater risk of developing HZ compared to the patients who did not receive chloroquine diphosphate treatment.

Clinical evaluation and dermatome locations of herpes zoster
------------------------------------------------------------

[Table 5](#t5-cln_68p621){ref-type="table"} shows the dermatome locations of HZ, as well as the clinical evaluations. Six cases had simultaneous involvement of two dermatomes. Neurological sequelae occurred in 14 (58.3%) of 24 patients, and no cases of HZ recurrence were reported. The duration of the neurological symptoms was 8.2±4.4 years.

The demographics, disease status and clinical and laboratory features were comparable in the patients with and without postherpetic neuralgia. However, the latter group used a higher prednisone dose at the time of the HZ diagnosis (median 40 mg/day \[range 5-70\]) than the former group (median 15 mg/day \[range 0--40\], *p* = 0.018, with OR of 0.93 and 95% CI of 0.86--0.99).

DISCUSSION
==========

The present study identified chloroquine diphosphate as the primary risk factor for HZ in DM/PM. In our population, we noted a high HZ prevalence that predominantly affected women and individuals with DM.

An important aspect of this retrospective study\'s design was its large cohort of HZ cases and associated risk factors in the patients with DM and PM, which are both considered rare systemic autoimmune diseases. Additionally, the study and control groups were matched by age because there is a known HZ cluster disparity between young and elderly subjects. Moreover, gender, disease type (DM or PM), age at diagnosis and disease duration were also controlled for by sample matching to avoid a confounding bias.

Despite enrolling large samples, many authors have found few HZ cases in their DM/PM populations. Notably, Marie et al. ([@b14-cln_68p621]) identified only three individuals with HZ in 279 cases and Yu et al. ([@b18-cln_68p621]) detected two subjects with HZ among 192 cases of DM/PM, whereas Fardet et al. ([@b13-cln_68p621]) found 16 HZ cases among 121 DM patients. In the present study, we evaluated 24 (10.4%) HZ cases among 230 patients who were clinically diagnosed with DM/PM over a 21-year follow-up period. Therefore, a considerable number of infected patients were identified in this population.

Based on other systemic autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis, the major risk factors for developing HZ include older age, use of corticosteroids and immunosuppressive agents, disease activity, female sex, cancer, lung disease and impaired cellular immunity ([@b3-cln_68p621]--[@b12-cln_68p621]--[@b21-cln_68p621]).

In our population, HZ predominantly affected adults with a mean age of 44 years (range 21 to 84 years), with no tendency toward affecting older individuals. Moreover, to avoid analysis bias, individuals with neoplasias were excluded.

In contrast with other systemic autoimmune diseases, in which impaired cellular immunity is considered a risk factor for HZ development ([@b12-cln_68p621]), humoral immunity function might be considered relevant in inflammatory myopathies because the prevalence of HZ was higher in the DM patients compared to the PM patients. From an immunopathological standpoint, CD8 (+) lymphocyte and macrophage infiltrations are primarily found in PM muscle fibers ([@b22-cln_68p621]), whereas in DM, B cells play important roles in the pathogenesis of the disease through the presence of autoantibodies, immune complex deposition in the dermoepidermal junction of skin lesions and the presence of B cells in inflamed muscles and perivascular areas ([@b23-cln_68p621],[@b24-cln_68p621]). Additionally, deposition of complement and immunoglobulin in the perifascicular endothelium can lead to ischemia and muscle atrophy, underlining the importance of humoral immunity ([@b25-cln_68p621]). Thus, disturbances in humoral immunity might increase HZ reactivation, as we found a higher prevalence of HZ in the DM patients compared to the PM patients.

Nagaoka et al. ([@b15-cln_68p621]) analyzed five HZ cases among 22 DM/PM patients and noted that the infection affected more patients without disease activity; they found no correlation over time with corticosteroid use. Our results showed that HZ prevalence was independent of disease status and clinical and laboratory features, including cutaneous manifestations. Moreover, daily and/or cumulative dosages of corticosteroid and/or intravenous pulse methylprednisolone did not increase the risk for HZ development in our population. Likewise, using immunosuppressive therapy (methotrexate, azathioprine, mycophenolate mofetil, leflunomide and cyclophosphamide)---either alone or in combination---was not associated with HZ.

However, patients using chloroquine diphosphate had a fivefold greater risk of developing HZ compared to patients not receiving chloroquine diphosphate treatment. Chloroquine diphosphate and its analogue, hydroxychloroquine, are used to treat various rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, dermatomyositis, Sjögren\'s syndrome, chronic juvenile arthritis and psoriatic arthritis; these drugs offer clinical benefits with acceptable safety profiles ([@b26-cln_68p621]--[@b29-cln_68p621]). Further, these drugs have also been used to treat inflammatory myopathies, particularly for the cutaneous symptoms of DM ([@b30-cln_68p621]--[@b34-cln_68p621]).

Chloroquine might also have antiviral activity ([@b35-cln_68p621]). As a lysosomotropic weak base, it impairs the replication of some viruses by reducing the efficiency of endosome-mediated virus entry or by inhibiting low-pH--dependent proteases in trans-Golgi vesicles ([@b35-cln_68p621]). Its antiviral activity against the human immunodeficiency virus ([@b36-cln_68p621]) and the SARS coronavirus has also been demonstrated ([@b37-cln_68p621],[@b38-cln_68p621]). However, chloroquine has also been shown to increase symptom severity and mortality (e.g., following Semliki Forest virus and encephalomyocarditis virus infection, as well as increasing viral titers in various organs) ([@b39-cln_68p621]). Our results clearly showed that chloroquine was a risk factor for HZ development in subjects with DM/PM, independent of disease status, therapy and demographic features.

Regarding the clinical evaluation, at least half of our patients had neurological sequelae. Six patients had simultaneous involvement of two dermatomes, while no cases of HZ recurrence were reported. Postherpetic neuralgia can result in severe pain such that patients are often unable to wear clothing that comes in contact with the lesions or be exposed to wind because of high skin sensitivity in regions such as the thorax and face. The incidence of postherpetic neuralgia rises from 10% among individuals of all ages to as high as 40% among those aged 50 years and older ([@b40-cln_68p621]). A large prospective study identified four independent predictors of postherpetic neuralgia: older age, severe, acute pain, severe rash and a shorter duration of rash before consultation ([@b41-cln_68p621]). Although controversial, short-term use of corticosteroids can reduce the pain severity and improve patient quality of life in the acute phase ([@b42-cln_68p621]). Note that high prednisone doses at the time of HZ diagnosis were found to decrease the incidence of postherpetic neuralgia in our patients.

In conclusion, our data showed a high prevalence of HZ in the DM/PM population studied and confirmed that chloroquine diphosphate is a risk factor for HZ development in this population, particularly women and DM patients. Further research is necessary to evaluate the possible molecular mechanism underlying the higher HZ prevalence in DM subjects compared to PM patient populations.

ACKNOWLEDGMENTS
===============

This study was partially supported by the Federico Foundation.

No potential conflict of interest was reported.

###### 

Comparison of the general demographic and clinical features of the dermatomyositis/polymyositis patients with and without herpes zoster.

                                                           HZ (+)           HZ (−)           *p-*value
  -------------------------------------------------------- ---------------- ---------------- -----------
  DM:PM ratio                                              19:5             113:87           0.046
  Sex at disease onset ± SD (years)                        43.8±16.8        42.2±14.2        0.123
  Gender - female (%)                                      7 (71)           157 (97)         1.000
  Time between disease diagnosis and symptoms (IQR) (mo)   5.0 (2.0--9.0)   3.0 (2.0--6.0)   0.264
  Cumulative clinical manifestations                                                         
  Constitutional symptoms (%)                              15 (63)          105 (51)         0.521
  Bedrest (%)                                              3 (13)           55 (27)          0.212
  Articular: arthralgia/arthritis (%)                      12 (50)          88 (43)          0.521
  Gastrointestinal tract: dysphagia (%)                    8 (34)           74 (36)          1.000
  Pulmonary: dyspnea (%)                                   5 (21)           56 (27)          0.766

DM: dermatomyositis; HZ: herpes zoster; IQR: interquartile range; PM: polymyositis; SD: standard deviation.

###### 

Demographic and clinical features of selected patients with dermatomyositis/polymyositis according to the presence of herpes zoster.

                                                           HZ (+)             HZ (−)                                                       *p*-value
  -------------------------------------------------------- ------------------ ------------------------------------------------------------ -----------
  DM: PM ratio                                             19:5               38:10                                                        1.000
  Age at disease onset ± SD (years)                        43.8±16.8          44.1±15.3                                                    0.935
  Gender - female (%)                                      7 (71)             14 (71)                                                      1.000
  Time between disease diagnosis and symptoms (IQR) (mo)   5.0 (2.0--9.0)     3.0 (3.0--8.5)[\*](#tfn2-cln_68p621){ref-type="table-fn"})   0.855
  Time between HZ and disease diagnosis (IQR) (mo)         13.0 (6.0--31.0)   9.5 (5.9--19.0)                                              0.190
  Cumulative clinical manifestations                                                                                                       
  Constitutional symptoms (%)                              15 (63)            24 (50)                                                      0.393
  Bedrest (%)                                              3 (13)             11 (23)                                                      0.290
  Cutaneous                                                                                                                                
  Heliotrope (%)                                           19 (79)            33 (69)                                                      0.158
  Gottron\'s papules (%)                                   19 (79)            34 (71)                                                      1.000
  Vasculitis (%)                                           6 (25)             6 (13)                                                       0.325
  Calcinosis (%)                                           3 (13)             1 (2)                                                        0.140
  Ulcers (%)                                               3 (13)             6 (13)                                                       0.269
  Photosensitive (%)                                       12 (50)            20 (42)                                                      1.000
  Articular: arthralgia/arthritis (%)                      12 (50)            16 (33)                                                      0.171
  Gastrointestinal tract: dysphagia (%)                    8 (34)             22 (46)                                                      0.310
  Pulmonary: dyspnea (%)                                   5 (21)             12 (25)                                                      0.766

Comparable period for patients who developed herpes zoster.

DM: dermatomyositis; HZ: herpes zoster; IQR: interquartile range; PM: polymyositis; SD: standard deviation.

###### 

Disease status and laboratory features of patients with dermatomyositis/polymyositis according to the presence of herpes zoster.

                                     HZ (+)                  HZ (−)                                                             *p-*value
  ---------------------------------- ----------------------- ------------------------------------------------------------------ -----------
  Disease status                                                                                                                
  Complete clinical response         2 (8)                   6 (13)                                                             0.596
  Partial clinical response          20 (83)                 37 (77)                                                            0.538
  Clinical remission                 2 (8)                   7 (15)                                                             0.450
  Laboratory features                                                                                                           
  Creatine kinase (U/L)                                                                                                         
  At diagnosis                       761.1 (254.0--4300.0)   3031.0 (148.0--9015.0)                                             0.449
  At HZ event                        178.5 (82.5--672.0)     14.0 (10.5--60.8)[\*](#tfn4-cln_68p621){ref-type="table-fn"})      0.304
  Aldolase (U/L)                                                                                                                
  At diagnosis                       14.0 (7.5--49.5)        14.0 (10.5--60.8)                                                  0.583
  At HZ event                        6.3 (4.6--9.9)          5.6 (4.9--8.2)[\*](#tfn4-cln_68p621){ref-type="table-fn"})         0.594
  Aspartate aminotransferase (U/L)                                                                                              
  At diagnosis                       86.5 (42.0--238.0)      82.0 (39.0--184.0)                                                 0.898
  At HZ event                        45.9±46.5               51.9±59.2[\*](#tfn4-cln_68p621){ref-type="table-fn"})              0.641
  Alanine aminotransferase (U/L)                                                                                                
  At diagnosis                       63.5 (32.0--120.0)      63.0 (29.0--177.0)                                                 0.685
  At HZ event                        42.4±36.4               64.5±118.3[\*](#tfn4-cln_68p621){ref-type="table-fn"})             0.241
  Lactate dehydrogenase (U/L)                                                                                                   
  At diagnosis                       639.0 (390.0--1506.0)   714.0 (456.0--1109.0)                                              0.605
  At HZ event                        813.0 (386.5--736.0)    576.0 (450.0--623.0)[\*](#tfn4-cln_68p621){ref-type="table-fn"})   0.926
  At HZ event                                                                                                                   
  Leukocytes (mm^3^)                 7689.9±3662.7           7161.5±3129.0[\*](#tfn4-cln_68p621){ref-type="table-fn"})          0.550
  Neutrophils (mm^3^)                5875.0±3112.1           4874.3±2,759.0[\*](#tfn4-cln_68p621){ref-type="table-fn"})         0.193
  Lymphocytes (mm^3^)                1554.2±960.5            1523.6±955.8[\*](#tfn4-cln_68p621){ref-type="table-fn"})           0.900
  C-reactive protein (mg/dL)         4.9 (1.5--14.7)         2.1 (1.0--9.3)[\*](#tfn4-cln_68p621){ref-type="table-fn"})         0.080
  ESR (mm/1^st^ hour)                18.4±12.2               21.4±19.6[\*](#tfn4-cln_68p621){ref-type="table-fn"})              0.448
  Antinuclear factor (%)             15 (63)                 28 (58)                                                            0.734
  Anti-Jo-1 antibody (%)             3 (13)                  1 (2)                                                              0.069

Comparable period for patients who developed herpes zoster. Results expressed as the means ± standard deviation or as median (interquartile ratios).

ESR: erythrocyte sedimentation rate; HZ: herpes zoster; SD: standard deviation.

###### 

Drug use features of patients with dermatomyositis/polymyositis according to the presence of herpes zoster.

                                           HZ (+)      HZ (−)      *p-*value
  ---------------------------------------- ----------- ----------- -----------
  Corticosteroid                                                   
  Using (%)                                21 (87.5)   37 (77.1)   0.292
  Mean±SD (mg/day)                         26.5±20.0   30.3±27.1   0.515
  ≥20 mg/day                               14 (58.3)   26 (54.2)   0.805
  Cumulative dose\* (g)                    1.5±1.2     1.5±1.4     0.928
  Immunosuppressives                                               
  Azathioprine (%)                         12 (50.0)   18 (37.5)   0.310
  Mean±SD (mg/kg/day)                      2.4±0.2     2.4±0.3     0.721
  Methotrexate (%)                         6 (25.0)    19 (39.6)   0.220
  Mean±SD (mg/week)                        23.0±2.7    22.5±2.6    0.727
  Cyclosporine (%)                         1 (4.2)     1 (2.1)     0.612
  Mean±SD (mg/kg/day)                      2.0         2.0         1.000
  IVIG (%)                                 1 (4.2)     3 (6.3)     0.716
  Mean±SD (g/kg)                           2.0         2.0         1.000
  Leflunomide (%)                          1 (4.2)     0           0.154
  Mean±SD (mg/day)                         20.0        --          --
  Cyclophosphamide (%)                     4 (4.2)     2 (2.1)     0.612
  Mean±SD (g/m^2^ body surface)            0.8±0.2     0.7±0.3     0.795
  Mycophenolate mofetil (%)                1 (4.2)     0           0.154
  Mean±SD (g/day)                          3.0         --          --
  Chloroquine diphosphate (%)              9 (37.5)    5 (10.4)    0.006
  Mean±SD (mg/day)                         3.2±0.2     3.3±0.3     0.814
  Corticosteroid + immunosuppressive (%)                           
  Using (%)                                17 (70.8)   31 (64.6)   0.592
  Number of immunosuppressives                                     
  One (%)                                  16 (66.7)   28 (58.3)   0.494
  Two (%)                                  1 (4.2)     9 (18.8)    0.154
  Three (%)                                1(4.2)      0           0.131

HZ: herpes zoster; IVIG: intravenous immunoglobulin; SD: standard deviation;

Cumulative dose: past two months.

###### 

Dermatomes and outcomes of herpes zoster.

  Case   Localization                      HZ evaluation with neurological sequelae
  ------ --------------------------------- ------------------------------------------
  1      Left dorsal area                  Yes
  2      Nose, left lower limb (L5)        No
  3      Face, left lower limb (L5)        No
  4      Thoracic area, left upper limb    No
  5      Lower right limb (tibial nerve)   Yes
  6      Left dorsal (T11)                 Yes
  7      Left upper limb                   Yes
  8      Dorsal area                       Yes
  9      Left upper limb                   Yes
  10     Dorsal area                       No
  11     Dorsal area                       No
  12     Dorsal area, left lower limb      Yes
  13     Right dorsal area (T11)           Yes
  14     Left thoracic area                Yes
  15     Left thoracic area, abdomen       Yes
  16     Trigeminal nerve                  Yes
  17     Right lower limb                  No
  18     Gluteus (S1 and S2)               No
  19     Left thoracic area                Yes
  20     Left thoracic area                Yes
  21     Left lower limb (S1)              No
  22     Trunk                             No
  23     Right thoracic area               No
  24     Left thoracic area (T4)           Yes

HZ: herpes zoster.

[^1]: Cunha GF participated in the data collection and writing of the manuscript. Souza FH participated in the writing of the manuscript. Levy-Neto M participated in the manuscript revision. Shinjo SK contributed to the study design and participated in the data collection and manuscript revision.
